Behrad Derakhshan
Corporate Officer/Principal at EDGEWISE THERAPEUTICS, INC.
Net worth: 229 919 $ as of 2024-05-30
Behrad Derakhshan active positions
Companies | Position | Start | End |
---|---|---|---|
EDGEWISE THERAPEUTICS, INC. | Corporate Officer/Principal | 2020-08-31 | - |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Director/Board Member | - | - |
Career history of Behrad Derakhshan
Former positions of Behrad Derakhshan
Companies | Position | Start | End |
---|---|---|---|
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 2019-06-30 | 2020-08-31 |
Therachon AG | Corporate Officer/Principal | 2017-03-31 | 2019-06-30 |
ALEXION PHARMACEUTICALS, INC. | Director/Board Member | 2014-12-31 | 2017-03-31 |
Dymedex Consulting LLC
Dymedex Consulting LLC Miscellaneous Commercial ServicesCommercial Services Dymedex Consulting LLC provides market development consulting services. It specializes in market analysis, strategic consulting and corporate integration. The company was founded in 2007 by Joseph Galatowitsch and Ross Meisner and is headquartered in St. Paul, MN. | Corporate Officer/Principal | 2012-09-30 | 2014-12-31 |
Training of Behrad Derakhshan
University of Surrey | Undergraduate Degree |
Weill Cornell Medicine | Doctorate Degree |
Statistics
International
United States | 4 |
Switzerland | 3 |
United Kingdom | 2 |
Operational
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
EDGEWISE THERAPEUTICS, INC. | Health Technology |
Private companies | 5 |
---|---|
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Therachon AG | |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Dymedex Consulting LLC
Dymedex Consulting LLC Miscellaneous Commercial ServicesCommercial Services Dymedex Consulting LLC provides market development consulting services. It specializes in market analysis, strategic consulting and corporate integration. The company was founded in 2007 by Joseph Galatowitsch and Ross Meisner and is headquartered in St. Paul, MN. | Commercial Services |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Health Technology |
- Stock Market
- Insiders
- Behrad Derakhshan
- Experience